Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OLR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OLR1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View OLR1 Products |
| Gene Delivery | OLR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation preserved for cell-based assays. |
View OLR1 Products |
| Benchmark Ab | Anti-OLR1 (Sequence of Clinical/Research Benchmarks) Recombinant positive control for assay validation. |
View OLR1 Products |
| Validator | OLR1 siRNA Set For knockdown verification and specificity profiling. |
View OLR1 Products |
| Related Target A | PCSK9 Synergistic cardiovascular pathway targeting lipid metabolism and LDL clearance. |
View PCSK9 Products |
| Related Target B | CD36 Co-scavenger receptor involved in oxLDL uptake and macrophage foam cell formation. |
View CD36 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily/homolog counter screening (C-type lectins) | Homolog panel proteins strictly sequence-verified and expressed in mammalian hosts. |
| Lack of reliable positive controls | Sequence-derived clinical benchmark antibodies included in the catalog. |
| False positive signaling in phenotypic assays | Sequence-verified siRNA sets included for target-specific knockdown verification. |
Live OLR1/LOX-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OLR1 (Lectin-like oxidized LDL receptor 1, LOX-1) therapeutics is intensifying, with major players shifting focus from traditional cardiovascular indications to oncology and immuno-oncology applications. OLR1 is highly expressed on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) within the tumor microenvironment, making it a highly sought-after target for reversing immunosuppression. As first-generation lipid-lowering therapies reach maturity, the next wave of R&D is targeting OLR1 using multi-specific modalities, antibody-drug conjugates (ADCs), and nucleic acid therapeutics to address both atherothrombosis and cancer-associated immune evasion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Amgen, Daiichi Sankyo, Academic Institutions | Atherosclerosis, Acute Coronary Syndrome, Solid Tumors | Ligand-blocking assays (Requires high-purity, natively glycosylated OLR1 ECD-Fc to mimic physiological oxLDL binding) |
| siRNA / RNAi | Alnylam, Arrowhead Pharmaceuticals | Hypercholesterolemia, Inflammatory Vascular Diseases | In vitro knockdown verification (Requires sequence-verified OLR1 siRNA and Lentivirus for stable cell line construction) |
| Bispecific / Multi-specific | Biotech Startups, Immuno-oncology Pioneers | Metastatic Solid Tumors (targeting PMN-MDSCs) | Dual-binding and bridging assays (Requires high-purity, endotoxin-controlled ortholog proteins for cross-reactivity profiling) |